drugset / Trial / NCT00914433

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers

NCT00914433 ↗

Phase 1 Withdrawn Syntara
NaSingle-groupTriple-blindTreatment

Summary

This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D \& 7A in blood and in sputum.

Timeline

Start
2009-04
Primary completion
2009-12
Completion
2010-04

Outcome

Outcome not reported

Stopped: “Drug development suspended”

Drugs

EvaluationDrugModalityDoseRoute
Subject TPI 1100 Unknown — Inhaled